Tesamorelin in the US: The GHRH Analog With Approved-Drug Data

Tesamorelin is a synthetic analog of human growth-hormone-releasing hormone, the full 44-residue GHRH(1-44) sequence with a trans-3-hexenoyl group attached at the N-terminal tyrosine. That single acyl modification is the whole design: it blocks dipeptidyl peptidase-4 cleavage at the N-terminus, which is the degradation route that gives native GHRH a half-life of a few minutes.

It acts at the GHRH receptor on pituitary somatotrophs, stimulating endogenous GH release rather than supplying exogenous GH. That distinction is the basis of the whole GHRH-analog class: the pituitary's own feedback loops remain in the circuit.

Research Material

Forty-four residues, around 5136 Da, N-terminally acylated. This is one of the longest peptides in the catalog and correspondingly one of the harder syntheses, with deletion sequences as the dominant impurity class. It is also the compound where an incomplete acylation is most consequential, because the acyl group is the entire reason the analog exists.

Amino Acid Sequence

Chemical Structure

Stated as findings from named, published, randomized trials conducted with pharmaceutical-grade material:

• ·Phase 3, HIV-associated lipodystrophy. Falutz et al., New England Journal of Medicine 2007: a 26-week randomized, double-blind, placebo-controlled trial in patients with HIV and excess abdominal fat, reporting reduction in visceral adipose tissue against placebo.[1]
• ·Pooled phase 3 analysis. Falutz et al. (2010) reported the pooled results of the tesamorelin phase 3 program, including the extension period and the effect of withdrawal.[2]
• ·Hepatic fat. Stanley et al., Lancet HIV 2019: a randomized, double-blind, multicenter trial reporting reduction in hepatic fat fraction and effects on fibrosis progression in people with HIV and non-alcoholic fatty liver disease.[3]

The tesamorelin trial program was conducted in people with HIV, on an approved GMP product, for indications defined in that population. It is not a general characterization of the molecule, and it is not evidence about a research vial. the FDA authorization, where it exists for a tesamorelin product, attaches to that product through the pharmacy channel, not to research material.

Research-grade tesamorelin is a laboratory material with no human-use authorization. The existence of an approved sibling product makes this distinction more important here, not less.

Identity by mass spectrometry against the expected mass near 5136 Da, HPLC purity, and measured content against the labeled amount. At 44 residues, purity is the figure that carries the most information about synthesis quality, because deletion sequences accumulate with chain length and a genuinely high purity number on a peptide this long is a meaningful signal.

Every Eppix tesamorelin lot is tested by Janoshik Analytical, published before sale and verifiable on the laboratory's own database. Multiple strengths are stocked; use the buttons under the certificate to switch.

Published Certificate

Select strength

10mg20mg

Batch

TESA-CA-26A-01

Purity (HPLC)

98.763%

Measured content

11.68 mglabeled 10 mg

Laboratory

Janoshik

Verify on the lab’s own databaseAll published certificates

Domestic fulfillment is by FedEx, typically one to three business days across the United States, free over $200 USD, with card and PayPal checkout and mix-and-match pricing at 5 and 10 vials.

The other GHRH-analog guides are buy sermorelin in the US and buy CJC-1295 and ipamorelin in the US.

Available at Eppix Labs

Tesamorelin

10mg · 20mg

Every batch tested by an independent laboratory, with the certificate published before sale.

From $59.99 USDIn stock